Literature DB >> 15161581

Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.

Dawn Hershman1, Rashmi Narayanan.   

Abstract

Advances in cancer treatment have resulted in improved life expectancies for survivors of breast and prostate cancer. As the number of cancer survivors grows, the long-term side effects of treatment play an increasingly prominent role in the routine care of these patients. Due to similar management approaches, survivors of breast and prostate cancer are at increased risk for osteoporosis. This review summarizes the prevention and management of osteoporosis and osteopenia resulting from cancer treatment in survivors of breast and prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15161581     DOI： 10.1007/s11912-004-0036-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  59 in total

1.  Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.

Authors:  T J Powles; E McCloskey; A H Paterson; S Ashley; V A Tidy; A Nevantaus; K Rosenqvist; J Kanis
Journal:  J Natl Cancer Inst       Date:  1998-05-06       Impact factor: 13.506

2.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

Authors:  C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

3.  Mortality after all major types of osteoporotic fracture in men and women: an observational study.

Authors:  J R Center; T V Nguyen; D Schneider; P N Sambrook; J A Eisman
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

4.  Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.

Authors: 
Journal:  JAMA       Date:  1996-11-06       Impact factor: 56.272

5.  Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study.

Authors:  M C Chapuy; R Pamphile; E Paris; C Kempf; M Schlichting; S Arnaud; P Garnero; P J Meunier
Journal:  Osteoporos Int       Date:  2002-03       Impact factor: 4.507

6.  Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.

Authors:  P D Delmas; R Balena; E Confravreux; C Hardouin; P Hardy; A Bremond
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

7.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer.

Authors:  H W Daniell; S R Dunn; D W Ferguson; G Lomas; Z Niazi; P T Stratte
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

8.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

9.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

10.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

Authors:  T J Powles; T Hickish; J A Kanis; A Tidy; S Ashley
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544
View more
  3 in total

1.  Systematic screen with kinases inhibitors reveals kinases play distinct roles in growth of osteoprogenitor cells.

Authors:  Ni-Rong Bao; Meng Lu; Fan-Wen Bin; Zhi-Yong Chang; Jia Meng; Li-Wu Zhou; Ting Guo; Jian-Ning Zhao
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

2.  The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.

Authors:  Allan Lipton; Robert Uzzo; Robert J Amato; Georgiana K Ellis; Behrooz Hakimian; G David Roodman; Matthew R Smith
Journal:  J Natl Compr Canc Netw       Date:  2009-10       Impact factor: 11.908

3.  Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.

Authors:  Ken Tawara; Julia T Oxford; Cheryl L Jorcyk
Journal:  Cancer Manag Res       Date:  2011-05-18       Impact factor: 3.989
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.